Agios Pharmaceuticals, Inc.

AGIO · NasdaqGS

Price$0.00+0.00 (+0.00%)

Price History

Volume & Moving Averages

Price50D200D

Analyst Price Target

$0.00▲ 0.0% above current price

Range: $0.00 – $0.00 · 0 analysts

Based on Wall Street analyst estimates — not a Stockinder prediction.

About the company

Jarvis is thinking

Key Metrics

Report card

Open as standalone page ↗

Jarvis is thinking

Recent Notable Coverage

Jarvis is thinking

Report Card

Growth

Health

Risk

–

Value

Quality

Ownership

Insider and institutional holdings, from Yahoo Finance — for Indian companies this roughly tracks promoter (insiders) and combined FII/DII (institutions) stakes, though not split out the same way a shareholding-pattern filing would.

Insiders1.1%

Institutions112.3%

Public / Other

Income Statement

	2025-12-31	2024-12-31	2023-12-31	2022-12-31	2021-12-31	2020-12-31	2019-12-31	2018-12-31	2017-12-31	2016-12-31
Total money the company brought in from its core business during the period, before any costs are subtracted.	$54.03M	$36.50M	$26.82M	$14.24M	–	$203.20M	$117.91M	$94.39M	$43.01M	–
The direct costs of producing what was sold — raw materials, manufacturing, direct labor.	$6.34M	$4.17M	$2.88M	$1.70M	–	$2.81M	$1.32M	$1.40M	–	–
Profit from core operations after subtracting the cost of revenue and operating expenses like R&D and marketing, but before interest and taxes.	-$472.13M	-$425.74M	-$391.49M	-$389.05M	-$378.42M	-$316.15M	-$426.33M	-$362.48M	-$320.79M	-$200.99M
Operating income as a percentage of revenue.	-873.9%	-1166.5%	-1459.5%	-2732.1%	–	-155.6%	-361.6%	-384.0%	-745.8%	–
The company's bottom-line profit after all expenses, interest, and taxes are subtracted.	-$412.78M	$673.73M	-$352.09M	-$231.80M	$1.60B	-$327.37M	-$411.47M	-$346.03M	-$314.67M	-$198.47M
Net income divided by the number of shares outstanding — profit attributable to each share.	$-7.00	$11.00	$-6.00	$-4.00	$26.55	$-4.74	$-6.00	$-6.03	$-6.00	$-5.00
Like basic EPS, but accounts for shares that could be created from stock options or convertible securities — a more conservative per-share profit figure.	$-7.00	$11.00	$-6.00	$-4.00	$26.55	–	–	–	–	–

Balance Sheet

	2025-12-31	2024-12-31	2023-12-31	2022-12-31	2021-12-31	2020-12-31	2019-12-31	2018-12-31	2017-12-31	2016-12-31
Cash and highly liquid short-term investments the company can access almost immediately.	$89.13M	$76.25M	$88.20M	$139.26M	$203.13M	$127.44M	$80.93M	$70.50M	$102.72M	$160.75M
Everything the company owns that has value — cash, property, inventory, investments, and more.	$1.30B	$1.66B	$937.12M	$1.24B	$1.44B	$852.95M	$890.74M	$858.46M	$614.40M	$619.09M
Everything the company owes — debt, unpaid bills, and other obligations.	$104.11M	$122.24M	$126.10M	$137.90M	$145.76M	$453.45M	$250.21M	$170.92M	$238.89M	–
What would be left for shareholders if the company sold all its assets and paid off all its debts — total assets minus total liabilities.	$1.19B	$1.54B	$811.02M	$1.10B	$1.29B	$399.50M	$640.53M	$687.54M	$375.50M	$358.59M

Cash Flow Statement

	2025-12-31	2024-12-31	2023-12-31	2022-12-31	2021-12-31	2020-12-31	2019-12-31	2018-12-31	2017-12-31	2016-12-31
Actual cash generated by the core business, as opposed to accounting profit, which can include non-cash items.	-$372.98M	-$389.84M	-$296.06M	-$309.48M	-$314.09M	-$290.76M	-$370.62M	-$304.42M	-$285.23M	$38.56M
Cash spent on physical assets like property, equipment, and infrastructure to maintain or grow the business.	$4.32M	$1.69M	$999000	$4.88M	$5.74M	$14.91M	$12.17M	$6.99M	$4.63M	$9.91M
Cash left over after capital expenditures — money the company could use for dividends, buybacks, debt repayment, or reinvestment.	-$377.29M	-$391.53M	-$297.06M	-$314.36M	-$319.83M	-$305.67M	-$382.79M	-$311.41M	-$289.86M	$28.65M

	You	Peer avg
Revenue Growth	+259.3%	+120.5%
ROE	-34.3%	-65.7%

Agios Pharmaceuticals, Inc.

Price History

Volume & Moving Averages

Analyst Price Target

About the company

Key Metrics

Report card

Jarvis Analysis

Recent Notable Coverage

Report Card

Ownership

Quick Actions

Reports & Coverage

Con Call Reports

Board of Directors / Annual Reports

Recent Articles

Income Statement

Balance Sheet

Cash Flow Statement

Peer Comparison